Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research

Niki BioSolutions' subsidiary DiamiR Biosciences signed an agreement to perform APOE genotyping for Charter Research, a multi-site clinical research network running Alzheimer's and other trials in Florida and Chicago. The tests will run on Niki's CAP-accredited and New York State CLEP-approved platform, and APOE status is increasingly required for eligibility and risk stratification in Alzheimer's trials.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.